International union of basic and clinical pharmacology CIV: The neurobiology of treatment-resistant depression: From antidepressant classifications to novel pharmacological targets

F. Caraci, F. Calabrese, R. Molteni, L. Bartova, M. Dold, G. M. Leggio, C. Fabbri, J. Mendlewicz, G. Racagni, S. Kasper, M. A. Riva, F. Drago

Research output: Contribution to journalReview article

Abstract

Major depressive disorder is one of the most prevalent and life-threatening forms of mental illnesses and a major cause of morbidity worldwide. Currently available antidepressants are effective for most patients, although around 30% are considered treatment resistant (TRD), a condition that is associated with a significant impairment of cognitive function and poor quality of life. In this respect, the identification of the molecularmechanisms contributing to TRD represents an essential step for the design of novel and more efficacious drugs able to modify the clinical course of this disorder and increase remission rates in clinical practice. New insights into the neurobiology of TRD have shed light on the role of a number of different mechanisms, including the glutamatergic system, immune/inflammatory systems, neurotrophin function, and epigenetics. Advances in drug discovery processes in TRD have also influenced the classification of antidepressant drugs and novel classifications are available, such as the neurosciencebased nomenclature that can incorporate such advances in drug development for TRD. This reviewaims to provide an up-to-date description of key mechanisms in TRD and describe current therapeutic strategies for TRD before examining novel approaches that may ultimately address important neurobiological mechanisms not targeted by currently available antidepressants. All in all, we suggest that drug targeting different neurobiological systems should be able to restore normal function but must also promote resilience to reduce the long-termvulnerability to recurrent depressive episodes.

Original languageEnglish
Pages (from-to)475-504
Number of pages30
JournalPharmacological Reviews
Volume70
Issue number3
DOIs
Publication statusPublished - Jul 1 2018

    Fingerprint

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Caraci, F., Calabrese, F., Molteni, R., Bartova, L., Dold, M., Leggio, G. M., Fabbri, C., Mendlewicz, J., Racagni, G., Kasper, S., Riva, M. A., & Drago, F. (2018). International union of basic and clinical pharmacology CIV: The neurobiology of treatment-resistant depression: From antidepressant classifications to novel pharmacological targets. Pharmacological Reviews, 70(3), 475-504. https://doi.org/10.1124/pr.117.014977